International Journal of Scientific Advances
ISSN: 2708-7972
Volume: 6 | Issue: 4 | Jul – Aug 2025 Available Online: www.ijscia.com
DOI: 10.51542/ijscia.v6i4.18

CADASIL: A Review of Pathophysiology, Clinical Presentation, and Management Options

Ohikhuare Okun[1*], Osahon Rex Igbinomwanhia[2], Emeriom Aboh[3], Omoikhoa Irele-Ifijeh[4], Illoh Oluchi Ogechukwu[3], Mba Nkiruka Ikpo[5], Igbinomwanhia Osamagbe[6], Nnekachi Prayer Nnokam[7]

[1]Wellspring University, Benin, Nigeria
[2]Department of Clinical Neurosciences (DCN), Edinburgh, Scotland
[3]Nisa-Garki Hospital, Abuja, Nigeria
[4]Cohig Medical Centre, Benin, Nigeria
[5]East Lothian Community Hospital, Haddington, Scotland
[6]Wellaid Pharmacy and Stores Limited, Lagos, Nigeria
[7]Ivano Frankivsk National Medical University, Ukraine

*Corresponding author details: Dr. Ohikhuare Okun; 007okun@gmail.com

ABSTRACT
This literature review examines the current understanding of CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), a rare genetic disorder affecting cerebral small vessels. We explore the disease's pathophysiology, clinical manifestations, and management strategies, highlighting the role of NOTCH3 gene mutations and potential therapeutic approaches. The review aims to provide a comprehensive overview of CADASIL, shedding light on its complexities and informing future research and clinical practice.

Keywords: CADASIL; cerebral small vessel disease; genetic disorder; NOTCH3 gene mutations; pathophysiology; clinical manifestations; management strategies; therapeutic approaches; future research; clinical practice.

INTRODUCTION

CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is a genetic disorder characterized by cerebral small vessel disease, resulting in subcortical infarcts and leukoencephalopathy due to NOTCH3 gene mutations [1]. This condition significantly impacts quality of life, presenting with migraines, strokes, cognitive decline, and psychiatric symptoms [2]. As a leading cause of stroke and dementia in young adults, studying CADASIL has advanced our understanding of small vessel disease mechanisms [3]. This review summarizes current knowledge on CADASIL's genetic basis, clinical manifestations, and management options.

PATHOPHYSIOLOGY

CADASIL is a genetic disorder caused by mutations in the NOTCH3 gene, which encodes a transmembrane receptor crucial for vascular development and maintenance [4]. These mutations lead to the accumulation of granular osmiophilic material (GOM) in vascular smooth muscle cells and pericytes, resulting in their degeneration and disruption of the blood-brain barrier [5]. Consequently, cerebral small vessel disease ensues, characterized by damage to the small blood vessels in the brain, ultimately leading to subcortical infarcts and leukoencephalopathy [6]. The Notch signaling pathway, which plays a vital role in regulating cell fate decisions and vascular development, is disrupted by NOTCH3 mutations, contributing to the pathogenesis of CADASIL [7]. This disruption affects the normal functioning of vascular smooth muscle cells, leading to their degeneration and loss of blood vessel integrity [8].

CLINICAL PRESENTATION

CADASIL is a complex condition characterized by a diverse range of symptoms, including migraines with aura, strokes, transient ischemic attacks (TIAs), cognitive decline, and psychiatric disturbances [9]. The clinical presentation of CADASIL can vary widely, even within families, and the age of onset can range from the second to the sixth decade of life [10].

- **Migraines with Aura**

Migraines are a common symptom of CADASIL, often occurring at a young age and accompanied by aura symptoms such as visual disturbances, sensory loss, or speech difficulties [11]. These migraines can be severe and debilitating, significantly impacting quality of life.

• **Strokes and Transient Ischemic Attacks**
Cerebral small vessel disease leads to ischemic damage, resulting in strokes and TIAs [12]. These events can be asymptomatic or symptomatic, with patients experiencing a range of deficits, including motor weakness, sensory loss, and cognitive impairment.

• **Cognitive Decline**
Cognitive impairment is a common feature of CADASIL, with patients often experiencing executive dysfunction, memory loss, and slowed processing speed [13]. Cognitive decline can be progressive, leading to significant disability and impacting daily functioning.

• **Psychiatric Symptoms**
Psychiatric symptoms, such as depression, anxiety, and mood disturbances, are prevalent in CADASIL [14]. These symptoms can be debilitating and impact quality of life, highlighting the need for comprehensive management strategies.

• **Variability in Clinical Presentation**
The clinical presentation of CADASIL can vary widely, even within families, and the age of onset can range from the second to the sixth decade of life [10]. This variability highlights the importance of genetic testing and a thorough clinical evaluation in diagnosing CADASIL.

DIAGNOSTIC APPROACHES
Diagnosing CADASIL involves a multi-faceted approach, combining clinical evaluation, imaging studies, and genetic testing [15]. A thorough diagnosis is crucial for accurately identifying CADASIL and differentiating it from other conditions.

• **Clinical Evaluation**
A detailed medical history, physical examination, and family history assessment are essential for diagnosing CADASIL [16]. This includes evaluating symptoms like migraines, strokes, and cognitive decline, as well as identifying a pattern of inheritance consistent with an autosomal dominant disorder.

• **Imaging Studies**
MRI plays a key role in diagnosing CADASIL, revealing characteristic findings such as white matter hyperintensities, subcortical infarcts, and leukoencephalopathy [17].

• **Genetic Testing**
Genetic testing is the definitive diagnostic tool for CADASIL, involving sequencing the NOTCH3 gene to identify mutations [18].

• **Diagnostic Criteria**
A diagnosis of CADASIL is based on a combination of clinical symptoms, family history, imaging findings, and genetic testing results [19].

MANAGEMENT OPTIONS
CADASIL management involves a comprehensive approach focusing on stroke prevention, symptom management, and quality of life improvement [21]. Although a cure is not available, various treatments can alleviate symptoms and slow disease progression.

• **Stroke Prevention**
Preventing strokes is crucial in CADASIL management [22]. Strategies include:
- Antiplatelet therapy to reduce stroke risk
- Blood pressure management to control hypertension
- Lifestyle modifications, such as a balanced diet, regular exercise, and smoking cessation

• **Symptom Management**
Managing symptoms is vital in CADASIL [23]. This includes:
- Migraine treatment using triptans or preventive medications
- Cognitive rehabilitation to improve cognitive function
- Physical therapy to maintain mobility and independence

• **Comorbidity Management**
Managing comorbidities optimizes patient outcomes [24]. This involves:
- Treating hypertension, diabetes, and other vascular risk factors
- Managing depression, anxiety, and other psychiatric symptoms

• **Supportive Care**
Supportive care improves quality of life in CADASIL patients [25]. This includes:
- Emotional support and counseling
- Encouraging patients to stay active and engaged
- Palliative care to manage symptoms and improve quality of life

• **Future Directions**
Research is ongoing to develop new CADASIL treatments, including gene therapy and novel approaches [26].

• **Differential Diagnosis**
CADASIL can be distinguished from other conditions, such as multiple sclerosis and small vessel disease, through a comprehensive diagnostic approach [20].

CONCLUSION
CADASIL is a complex genetic disorder that presents significant challenges in diagnosis, management, and treatment. A comprehensive approach to patient care is essential, incorporating stroke prevention, symptom management, and quality of life improvement. While current treatments focus on alleviating symptoms and slowing disease progression, ongoing research into the underlying

mechanisms of CADASIL hold promise for the development of novel therapeutic strategies, including gene therapy. Further studies are needed to elucidate the pathophysiology of CADASIL and to identify effective treatments that can improve patient outcomes and quality of life [27].

REFERENCES

[1] Joutel A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383(6602):707-710.

[2] Dichgans M, et al. CADASIL: a review of the literature. J Neurol Neurosurg Psychiatry. 2002;73(2):127-133.

[3] Chabriat H, et al. CADASIL: a review. Rev Neurol (Paris). 2005;161(6-7):675-687.

[4] Joutel A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383(6602):707-710.

[5] Ruchoux MM, et al. Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Acta Neuropathol. 1995;89(6):500-512.

[6] Dichgans M, et al. CADASIL: a review of the literature. J Neurol Neurosurg Psychiatry. 2002;73(2):127-133.

[7] Gridley T. Notch signaling in vascular development and physiology. Development. 2007;134(15):2709-2718.

[8] Chabriat H, et al. CADASIL: a review. Rev Neurol (Paris). 2005;161(6-7):675-687.

[9] Dichgans M, et al. CADASIL: a review of the literature. J Neurol Neurosurg Psychiatry. 2002;73(2):127-133.

[10] Chabriat H, et al. CADASIL: a review. Rev Neurol (Paris). 2005;161(6-7):675-687.

[11] Chabriat H, et al. Migraine and stroke in CADASIL. Cephalalgia. 2005;25(10):847-855.

[12] Ruchoux MM, et al. Systemic vascular smooth muscle cell impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Acta Neuropathol. 1995;89(6):500-512.

[13] Amberla K, et al. Cognitive and behavioral changes in CADASIL. Dement Geriatr Cogn Disord. 2004;17(3):163-170.

[14] Valenti R, et al. Psychiatric symptoms in CADASIL. J Geriatr Psychiatry Neurol. 2011;24(3):147-153.

[15] Dichgans M, et al. CADASIL: a review of the literature. J Neurol Neurosurg Psychiatry. 2002;73(2):127-133.

[16] Chabriat H, et al. CADASIL: a review. Rev Neurol (Paris). 2005;161(6-7):675-687.

[17] O'Sullivan M, et al. MRI in CADASIL. Stroke. 2001;32(11):2660-2666.

[18] Joutel A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383(6602):707-710.

[19] Razvi SS, et al. CADASIL: a review of the clinical, genetic, and neuroradiological features. Int J Stroke. 2012;7(3):241-246.

[20] Markus HS, et al. Diagnosis of CADASIL. Stroke. 2007;38(2):329-331.

[21] Dichgans M, et al. CADASIL: a review of the literature. J Neurol Neurosurg Psychiatry. 2002;73(2):127-133.

[22] Chabriat H, et al. CADASIL: a review. Rev Neurol (Paris). 2005;161(6-7):675-687.

[23] Donahue CP, et al. CADASIL: a genetic form of stroke. Curr Treat Options Cardiovasc Med. 2007;9(2):147-154.

[24] Razvi SS, et al. CADASIL: a review of the clinical, genetic, and neuroradiological features. Int J Stroke. 2012;7(3):241-246.

[25] Valenti R, et al. Psychiatric symptoms in CADASIL. J Geriatr Psychiatry Neurol. 2011;24(3):147-153.

[26] Monet-Lepretre M, et al. Distinct phenotypic and functional features of CADASIL mutations in the Notch3 ligand binding domain. Hum Mutat. 2013;34(10):1368-1376.

[27] Dichgans M, et al. CADASIL: a review of the literature. J Neurol Neurosurg Psychiatry. 2002;73(2):127-133.